undamentalytics Newsletter
Sign in

Tevogen Inc. (TVGN) stock

Add to watchlist

Add holding +

NASDAQ: TVGN Nasdaq Biotechnology Next results ~November 13, 2026

Tevogen Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds20 adding, 20 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 431% in the quarter to 2025-12-31.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Tevogen Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 113% and a beta of 1.8 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$7.96 against an average estimate of -$1.50: missed by 430.7%
Share reaction
+17.6% in the first session after the results on April 26, 2024, against +1.3% for the S&P 500
Next report
November 13, 2026

Tevogen's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.3%
  • 1 week-10.6%
  • 1 month-19.9%
  • This year-66.2%
  • 1 year-82.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
April 26, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Announcement
  4. Leadership
  5. Governance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Tevogen Inc. valuation models and calculator

No model value for Tevogen Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Tevogen Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tevogen Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 13, 2026.

Analysts' consensus

No analyst estimates are published for Tevogen Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2025 −$1.50 −$7.96 −430.7%
Sept 2025 −$3.00 −$1.50 +50.0%
Jun 2025 −$2.50 −$1.50 +40.0%
Mar 2025 −$2.50 −$3.50 −40.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.5%
of tradable shares
Days to cover
10.52
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
72.1%
of shares
Employees
18
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 2023202420252026 to date
Return
TVGN+8%−91%−68%−66%
Industry peers (median)−18%−28%−5%−26%
S&P 500+26%+25%+18%+11%
Months that ended higher
TVGN75%17%17%27%
S&P 50067%75%75%46%
Largest fall from a high during the year
TVGN−8%−98%−80%−80%
S&P 500−10%−8%−19%−9%

Worst fall since January 5, 2022: 99% from March 6, 2023 to July 20, 2026. Getting back needed a 14514% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.89 – $29.40
From 52-week high
−81.0%
vs 50-day average
−19.5%
vs 200-day average
−31.3%
Volatility (1 year)
113%
Beta vs S&P 500
1.84

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±17.6%
After a week
1 up, 0 down
typical move ±14.1%
After a month
0 up, 1 down
typical move ±6.7%
Results releasedNext dayS&P 500 next day5 days21 days
April 26, 2024 +17.6% +1.3% +14.1% −6.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$608,675
Institutions reporting
30
Shares held vs prior quarter
▼ 20.9%
Positions opened / closed
14 / 12

Top buyers and sellers, Q2 2026: 20 institutions bought and 20 sold ; the biggest buyer was AQR Capital Management LLC (+17K shares) and the biggest seller Blackrock, Inc (−24K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $135,704 24K 22.3% ▼ 27.9%
Morgan Stanley $106,460 19K 17.5% ▲ 8.5%
AQR Capital Management LLC $97,561 17K 16.0% New
Goldman Sachs Group Inc $80,163 14K 13.2% New
Jane Street Group, LLC $63,251 11K 10.4% New
FMR LLC $55,615 10K 9.1% ▼ 3.3%
Russell Investments Group, Ltd. $36,971 7K 6.1% ▲ 12.5%
Tower Research Capital LLC (TRC) $8,456 1K 1.4% ▲ 58.8%
UBS Group AG $6,130 1K 1.0% ▼ 69.6%
Vanguard Fiduciary Trust Co $4,743 1K 0.8% ▼ 38.7%
Gamma Investing LLC $4,313 1K 0.7% ▲ 444.3%
Jpmorgan Chase & Co $2,473 0K 0.4% ▼ 18.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tevogen Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $6,635 3 trades by 1 insider · 0% under pre-set plans
Net ▼ $6,635 net selling
Insider Date Trade Shares Price Value
Flomenberg Neal See Remarks March 13, 2026 Sell 501 $6.40 $3,206
Flomenberg Neal See Remarks March 11, 2026 Sell 452 $7.26 $3,282
Flomenberg Neal See Remarks March 10, 2026 Sell 19 $7.75 $147

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • April 26, 2024

Recent SEC filings

Data status

When each part of this page on Tevogen Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Tevogen Inc. in brief

What does Tevogen Inc. do?
Tevogen Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Tevogen Inc.'s stock ticker?
Tevogen Inc. trades under the ticker TVGN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Tevogen Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Morgan Stanley and AQR Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Tevogen Inc. stock?
Over the last 12 months, Tevogen Inc.'s directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Tevogen Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tevogen Inc. announces its own schedule.